Ono Pharmaceutical Co., Ltd. · TSE:4528
Ono Pharmaceutical — Merger or Acquisition (April 2024)
27 slides from Ono Pharmaceutical's merger presentation, Apr 30, 2024
Slide 1: Merger Agreement with Deciphera Pharmaceuticals
Merger Agreement with Deciphera Pharmaceuticals April 30, 2024
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This communication relates to ONO Pharmaceutical co., ltd. (“ONO”), Deciphera Pharmaceuticals, Inc (“Deciphera”) and the proposed acquisition of Deciphera by ONO (the “Proposed Transaction”) and includes express or implied forward-looking statemen
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It The tender offer referenced in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Deciphera, nor is it a substitute for th
Slide 4: Agenda
Agenda 01 Transaction Summary 02 Ono’s Growth Strategy 03 Overview of Deciphera Pharmaceuticals, Inc. 04 Strategic Rationale of Acquisition 3 / 25
Slide 5: Transaction Summary
01 Transaction Summary
Slide 6: Transaction Summary
Transaction Summary Party Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) US $25.60 per share in cash; Total equity value of acquisition is approximately US $2.4 billion Purchase (Premium of 74.7% to Deciphera’s closing share price of US $14.65 on April 26, 2024, and premium of 68.8% Price to Deciphe
Slide 7: Ono's Growth Strategy
02 Ono’s Growth Strategy
Slide 8: Growth Strategy to Become Global Specialty Pharma
Growth Strategy to Become Global Specialty Pharma Aiming to be a ‘Global Specialty Pharma’ that consistently delivers innovative drugs worldwide, we strategically focus on enhancing our global pipeline and realizing direct sales in the U.S. and Europe Reinforcement of pipelines and acceleration of g
Slide 9: Growth Strategy to Become Global Specialty Pharma
Growth Strategy to Become Global Specialty Pharma Acquiring promising global pipelines and strengthening the overseas capability by M&A is means to accelerate our activity for growing towards a Global Specialty Pharma by realizing direct sales 1’) Development or acquisition of ANOTHER promising glob
Slide 10: Overview of Deciphera Pharmaceuticals, Inc.
03 Overview of Deciphera Pharmaceuticals, Inc.
Slide 11: Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) Company focusing on discovering, developing and commercializing new medicines for cancer, with rich pipeline of oral kinase inhibitors (founded 2003) Strong U.S. 【U.S.】 Waltham, Massachusetts (Headquarters), Lawrence, Kansas (Research) and European 【Eur
Slide 12: Deciphera's Strong Oncology Portfolio and Compelling Pipeline
Deciphera’s Strong Oncology Portfolio and Compelling Pipeline Proven track records in R&D and sales with 5 proprietary first in class or best in class products and pipelines in oncology therapeutic area Product and late-stage pipelines Sales expertise in the U.S. and Europe ⚫ QINLOCK® : approved in
Slide 13: Overview of QINLOCK
Overview of QINLOCK® Only approved drug for 4th line GIST1) in the U.S., Europe, and other countries around the globe The most common sarcoma of the gastrointestinal tract and Product Positioning present in the stomach or small intestine Characteristic The total number of annual cases in U.S. and Eu
Slide 14: Summary of INVICTUS Study: 4th line GIST
Summary of INVICTUS Study: 4th line GIST INVICTUS results showed a statistically significant improvement in PFS; clinically meaningful improvement in OS (BTD1)) Design A Phase 3, randomized, double-blind, placebo-controlled study (29 sites in 12 countries) Cohort QINLOCK® 150mg once daily (n=80), Pl
Slide 15: Exploratory Analysis From INTRIGUE Study: 2nd line GIST
Exploratory Analysis From INTRIGUE Study: 2nd line GIST Although the primary endpoint was not achieved, the results of this exploratory analysis demonstrate the impressive clinical efficacy for QINLOCK® in patients with KIT exon 11+17/18 mutations (BTD1) ) Design A phase 3, randomized, open-label, s
Slide 16: Market Potential of QINLOCK
Market Potential of QINLOCK® QINLOCK® business is in a growth phase with rising revenue; opportunity exists for significant upside potential with new indications and continued geographic expansion Revenue increase (quarterly) Expanding distribution channel in Europe Revenue has increased steadily qu
Slide 17: Overview of Vimseltinib
Overview of Vimseltinib Potential best-in-class CSF1R inhibitor preparing for NDA / MAA filing for TGCT1) in U.S. and Europe ⚫ Locally aggressive tumors in joints Product Positioning (U.S.) ⚫ High disease burden with surgery recurrence multiple symptoms including Systemic Treatment Characteristic se
Slide 18: Summary of MOTION Study: TGCT
Summary of MOTION Study: TGCT Demonstrated statistically significant improvement in ORR and met all six key secondary endpoints, including TVS1) and ROM2) Design A Phase 3, randomized, double-blind3), placebo-controlled study (35 sites in 13 countries) Cohort Vimseltinib 30mg twice weekly (n=83), Pl
Slide 19: Deciphera's Pipeline
Deciphera’s Pipeline Robust Pipeline from Deciphera’s Proprietary Switch Control Platform Pipeline Target Indication Stage Originator Switch Control Kinase Inhibitor Approved >40 countries GIST 4th line (US 2020, EU 2021) QINLOCK® KIT GIST 2nd line P3 KIT exon 11+17/18 TGCT Regulatory Submission Vim
Slide 20: Market Opportunity for Deciphera's pipeline
Market Opportunity for Deciphera’s pipeline QINLOCK® and Vimseltinib together are expected to represent a peak worldwide revenue opportunity of $1B; upside potential expected with label expansions and advancements of other early-stage assets DCC-3116 DCC-3116 : Target population ～10,000 patients4)
Slide 21: Deciphera's Strong U.S. and European Footprint
Deciphera’s Strong U.S. and European Footprint R&D and CMC functions are based in the U.S., and Commercial organization is Established in the U.S. and 6 European countries (355 employees in total 1)) United States [Head Office (Development / Regulatory / Sales / BD / CMC)] Location: Waltham, MA [Res
Slide 22: Strategic Rationale of Acquisition
04 Strategic Rationale of Acquisition
Slide 23: Strategic Rationale of Acquisition
Strategic Rationale of Acquisition The acquisition of Deciphera is a pivotal growth driver toward becoming a Global Specialty Pharma Reinforcement of ⚫ QINLOCK® ; launched product in U.S. and Europe ⚫ Secure short to mid-term revenue pipeline in oncology ⚫ Vimseltinib ; marketing applications in U.S
Slide 24: Brings Together Complementary Strength of Ono and Deciphera
Brings Together Complementary Strength of Ono and Deciphara Accelerate growth towards Global Specialty Pharma by leveraging strength of each company Accelerate growth towards Global Specialty Pharma Expertise of sales and development Expertise of sales and development Build a more robust presence in
Slide 25: Reinforcement of Global Pipeline through this transaction
Reinforcement of Global Pipeline through this transaction Enrichment of global pipelines1), especially in oncology field, which encourage us to strengthen franchises in the hematologic cancer and gastrointestinal areas PoC Pivotal Regulatory・Approval ONO-7475 ONO-4578 Leveraging QINLOCK®’s sales inf
Slide 26: Growth Strategy to Become Global Specialty Pharma
Growth Strategy to Become Global Specialty Pharma Counteracting the patent cliff and reinforcing our business capability in U.S and Europe, we expect to implement more global licensing deals or M&A to accelerate growth towards Global Specialty Pharma Booking QINLOCK® sales; Continuous pipeline Furth
Slide 27: Dedicated to the Fight against Disease and Pain
Dedicated to the Fight against Disease and Pain
Ono Pharmaceutical — Merger or Acquisition (April 2024) on 6ix